Trial Profile
Phase IIa, Placebo-controlled, Randomized, Double-blind, Crossover Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 (8%) Administered by Nebulization in Subjects With Mild Atopic Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2019
Price :
$35
*
At a glance
- Drugs Carbon dioxide/perflubron (Primary)
- Indications Allergic asthma; Asthma
- Focus Adverse reactions; Proof of concept
- Sponsors SolAeroMed
- 15 Feb 2019 Status changed from recruiting to completed.
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
- 06 Nov 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov